Skip to main content
. 2019 Nov 26;9:17601. doi: 10.1038/s41598-019-54033-0

Figure 2.

Figure 2

Hyperglycaemia- (a), hypertriglyceridemia- (b), hyper-low density lipoprotein (LDL)-cholesterolemia- (c), and hypercholesterolemia-free survival (d) by dasatinib, nilotinib and imatinib.